device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in an expansion cohort of the ALIGN-AR trial, paving the ...

It can lead to complications like left ventricular hypertrophy (LVH), diastolic dysfunction, and diastolic heart failure. Aortic regurgitation: This happens when the aortic valve doesn’t close ...

Especially, sound speed imaging in USTC has been documented to play a crucial role in the clinical diagnosis of breast cancer. Due to the high demand for resolution in medical applications, ...

Thus, it is not surprising that patients originally suspected of having mitral regurgitation are later revealed as having aortic stenosis instead. When a predominantly apical systolic murmur ...

[Image from the JenaValve website] The ALIGN-AR pivotal trial evaluated the JenaValve Trilogy replacement vavle in high-risk patients with symptomatic, severe aortic regurgitation (AR).

Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress ...

with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a ...

with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial’s ...